Stay updated with breaking news from Pharming Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Narcan, a nasal spray product that reverses the effects of opioid overdose, is now FDA approved for non-prescription use. Other recent FDA approvals include decisions for drugs from Pharming Group, Incyte, and Aurion Biotech.
Pharming Group (NASDAQ:PHAR – Get Rating) had its price target increased by Oppenheimer from $36.00 to $40.00 in a research report sent to investors on Tuesday, The Fly reports. Oppenheimer currently has an outperform rating on the stock. Oppenheimer also issued estimates for Pharming Group’s Q3 2023 earnings at $0.00 EPS, FY2025 earnings at $0.04 […]
Pharming Group (NASDAQ:PHAR – Get Rating) – Stock analysts at Oppenheimer dropped their FY2025 earnings per share estimates for Pharming Group in a research note issued on Tuesday, March 28th. Oppenheimer analyst H. Singh now anticipates that the company will post earnings per share of $0.04 for the year, down from their previous estimate of […]
Stock analysts at Royal Bank of Canada initiated coverage on shares of Pharming Group (NASDAQ:PHAR – Get Rating) in a note issued to investors on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the stock. A number of other research firms have also recently issued reports on PHAR. TheStreet cut Pharming Group […]
LEIDEN, The Netherlands, March 30, 2023 /PRNewswire/ -- Pharming Group N.V. announces that Pharming's Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will... | March 30, 2023